The Ultimate Injury Healing Protocol: KLOW + BPC-157 + TB-500
Three-phase layered approach to connective tissue repair research. All phases run concurrently from Day 1.
Protocol Overview
This protocol addresses tissue repair through three distinct but complementary mechanisms running simultaneously. The systemic KLOW blend creates the internal environment for healing. Localised BPC-157 targets the specific injury site directly. The acute TB-500 blast during the first month delivers the strongest anti-fibrotic and cell-migration stimulus at the most critical window of the repair process. No single compound achieves what the combination does.
Before starting: Establish a low-inflammation dietary baseline and adequate rest first. Peptides create the conditions for rapid healing. The lifestyle determines how well those conditions are exploited.
Phase 1 — Systemic Baseline: KLOW (Full 3 Months)
KLOW is a four-compound blend administered as a single nightly subcutaneous injection. It runs for the entire 3-month duration without interruption. Each compound addresses a different layer of the repair mechanism.
- BPC-157 — — drives angiogenesis, activates growth factor signalling in fibroblasts, supports gut-lining integrity which directly impacts systemic inflammation
- TB-500 — — provides systemic anti-inflammatory activity through actin regulation, supports whole-body cell migration to injured tissue
- KPV — — binds melanocortin receptors on immune cells, suppresses NF-kB signalling, reduces pro-inflammatory cytokines IL-1beta and TNF-alpha
- GHK-CU — — activates over 4,000 genes involved in tissue maintenance, stimulates collagen and elastin synthesis, modulates TGF-beta to prevent excessive scarring
| Compounds | BAC Water | Dose | Timing |
|---|---|---|---|
| 10mg BPC-157 + 10mg TB-500 10mg KPV + 50mg GHK-CU (3 vials total) | 3ml per vial | 10iu daily | Every night. Consistent timing critical. |
Phase 2 — Localised Target: BPC-157 (Full 3 Months)
BPC-157 is administered independently — injected at or near the injury site, not into subcutaneous fat. The KLOW blend provides systemic BPC-157 levels. This Phase 2 injection concentrates the compound exactly where tissue repair is most needed, exploiting its documented localised angiogenic and fibroblast activation capacity.
| Compound | BAC Water | Dose | Frequency |
|---|---|---|---|
| BPC-157 10mg ×3 | 2ml per vial | 5iu morning 5iu evening | Injected at injury site. Not subcutaneous fat. |
Phase 3 — Acute Blast: TB-500 (First Month Only)
TB-500 at a higher loading dose runs exclusively during month one. Its mechanism centres on actin regulation — actin being the protein that drives cell movement and tissue remodelling. Elevated TB-500 dramatically accelerates repair cell migration to damaged tissue, suppresses pro-inflammatory cytokines, and reduces fibrosis during the acute window when anti-fibrotic signalling produces the most significant structural changes.
| Compound | BAC Water | Dose | Frequency |
|---|---|---|---|
| TB-500 10mg ×2 | 2ml per vial | 3.33mg (33iu) | 2× per week — e.g. Monday and Thursday |